丙种球蛋白治疗重症肺炎合并血小板减少症的疗效分析

The efficacy of IVIG in the treatment of severe pneumonia with thrombo-cytopenia

目的:观察丙种球蛋白(IVIG)治疗重症肺炎合并血小板减少的疗效及安全性。方法:选取2014-08—2017-12期间在我院接受治疗的48例重症肺炎合并血小板减少症患者,随机分为对照组(28例)和治疗组(20例),对照组给予常规治疗,治疗组在常规治疗基础上给予静脉点滴IVIG(0.4g·kg^(-1)·d^(-1)),l次/d,连用3d,并观察两组患者血小板计数、机械通气时间、氧合指数改善情况、危重症评分(APACHEⅡ)、28d病死率及药物不良反应情况。结果:治疗组血小板上升幅度高于对照组、氧合指数及病情严重程度改善情况优于对照组、机械通气时间短于对照组,且差异有统计学意义(P<0.05或P<0.01);两组间28d病死率无差别,用药过程中未发现有药物不良反应。结论:IVIG治疗重症肺炎合并血小板减少症具有一定疗效,且安全性好。

Objective：To observe the efficacy and safety of IVIG in the treatment of severe pneumonia with thrombocytopenia.Method：Forty-eight cases of severe pneumonia complicated with thrombocytopenia from August2014 to December2017 in our hospital were randomly divided into control（n=28）and treatment（n=20）groups,patients in the control group were given routine treatment,while those in the treatment group were administered with IVIG（0.4 g·kg-1·d-1）for 3 days.The changes of platelet count,oxygenation index,mechanical ventilation time,APACHEⅡscore,28 d mortality and drug adverse reaction were observed.Result：The platelet counts of treatment group increased more than the control group,the oxygenation indexes were better than those of control group,the mechanical ventilation time was shorter than the control group（P〈0.05 or P〈0.01）,there were no significant difference of 28 dmortality between the two groups,and adverse drug reaction was not found in the treatment group.Conclusion：IVIG is effective and safe in the treatment of severe pneumonia with thrombocytopenia.